These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1424424)

  • 1. Clinical pharmacology of nicorandil in patients with congestive heart failure.
    Tice FD; Jungbluth GL; Binkley PF; MacKichan JJ; Mohrland JS; Wolf DL; Leier CV
    Clin Pharmacol Ther; 1992 Nov; 52(5):496-503. PubMed ID: 1424424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic effects of oral nicorandil in congestive heart failure.
    Tice FD; Binkley PF; Cody RJ; Moeschberger ML; Mohrland JS; Wolf DL; Leier CV
    Am J Cardiol; 1990 Jun; 65(20):1361-7. PubMed ID: 2140489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans.
    Giles TD; Pina IL; Quiroz AC; Roffidal L; Zaleski R; Porter RS; Karalis DG; Mohrland JS; Wolf DL; Hearron AE
    J Cardiovasc Pharmacol; 1992 Oct; 20(4):572-8. PubMed ID: 1280713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure.
    Tsutamoto T; Kinoshita M; Hisanaga T; Maeda Y; Maeda K; Wada A; Fukai D; Yoshida S
    Am J Cardiol; 1995 Jun; 75(16):1162-5. PubMed ID: 7762505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure.
    Larsen AI; Gøransson L; Aarsland T; Tamby JF; Dickstein K
    Am Heart J; 1997 Sep; 134(3):435-41. PubMed ID: 9327699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of nicorandil in patients with normal and impaired renal function.
    Molinaro M; Villa G; Regazzi MB; Salvadeo A; Segagni S; Rondanelli R; Sartirana E
    Eur J Clin Pharmacol; 1992; 42(2):203-7. PubMed ID: 1535591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic action of nicorandil in chronic congestive heart failure.
    Solal AC; Jaeger P; Bouthier J; Juliard JM; Dahan M; Gourgon R
    Am J Cardiol; 1989 Jun; 63(21):44J-48J. PubMed ID: 2525325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of nicorandil in congestive heart failure.
    Galié N; Varani E; Maiello L; Boriani G; Boschi S; Binetti G; Magnani B
    Am J Cardiol; 1990 Feb; 65(5):343-8. PubMed ID: 2137279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of nicorandil.
    Frydman AM; Chapelle P; Diekmann H; Bruno R; Thebault JJ; Bouthier J; Caplain H; Ungethuem W; Gaillard C; Le Liboux A
    Am J Cardiol; 1989 Jun; 63(21):25J-33J. PubMed ID: 2525322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure.
    Tsutamoto T; Kinoshita M; Nakae I; Maeda Y; Wada A; Yabe T; Horie H
    Am Heart J; 1994 Apr; 127(4 Pt 1):866-73. PubMed ID: 8154425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs.
    Ishizaki T; Chiba K; Suganuma T; Sasaki T; Kamiyama H; Nakano H
    J Pharm Sci; 1984 Apr; 73(4):494-8. PubMed ID: 6233416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The haemodynamic effects and pharmacokinetics of intravenous nicorandil in healthy volunteers.
    Wolf DL; Ferry JJ; Hearron AE; Froeschke MO; Luderer JR
    Eur J Clin Pharmacol; 1993; 44(1):27-33. PubMed ID: 8436151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris.
    Camm AJ; Maltz MB
    Am J Cardiol; 1989 Jun; 63(21):61J-65J. PubMed ID: 2525328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-related haemodynamic effects and pharmacokinetics of oral nicorandil in patients evaluated for chest pain.
    Arnold JM; Kowey PR; Wolf DL; Jungbluth GL; Hearron AE; Luderer JR
    Int J Cardiol; 1994 May; 44(3):203-15. PubMed ID: 8077066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.
    Döring G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S74-81. PubMed ID: 1282180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-performance liquid chromatographic method for stability and pharmacokinetic studies of nicorandil.
    Bachert EL; Fung HL
    J Chromatogr; 1993 Sep; 619(2):336-41. PubMed ID: 8263109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic profile of nicorandil in humans: an overview.
    Frydman A
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S34-44. PubMed ID: 1282174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.
    Frampton J; Buckley MM; Fitton A
    Drugs; 1992 Oct; 44(4):625-55. PubMed ID: 1281076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorimetric determination of nicorandil in human plasma by a high-performance liquid chromatographic-postcolumn ultraviolet irradiation [corrected] system equipped with on-line back-pressure tubing.
    Mawatari K; Nakamura Y; Shimizu R; Sate S; Iinuma F; Watanabe M
    J Chromatogr B Biomed Appl; 1996 Apr; 679(1-2):155-9. PubMed ID: 8998555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of coronary spasm by nicorandil: comparison with nifedipine.
    Lablanche JM; Bauters C; Leroy F; Bertrand ME
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S82-5. PubMed ID: 1282182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.